First Time Loading...

Kymera Therapeutics Inc
NASDAQ:KYMR

Watchlist Manager
Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc
NASDAQ:KYMR
Watchlist
Price: 32.845 USD -6.72%
Updated: Apr 25, 2024

Intrinsic Value

KYMR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. [ Read More ]

The intrinsic value of one KYMR stock under the Base Case scenario is 15.674 USD. Compared to the current market price of 32.845 USD, Kymera Therapeutics Inc is Overvalued by 52%.

Key Points:
KYMR Intrinsic Value
Base Case
15.674 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Kymera Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KYMR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Kymera Therapeutics Inc

Provide an overview of the primary business activities
of Kymera Therapeutics Inc.

What unique competitive advantages
does Kymera Therapeutics Inc hold over its rivals?

What risks and challenges
does Kymera Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Kymera Therapeutics Inc recently?

Summarize the latest earnings call
of Kymera Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kymera Therapeutics Inc.

Provide P/S
for Kymera Therapeutics Inc.

Provide P/E
for Kymera Therapeutics Inc.

Provide P/OCF
for Kymera Therapeutics Inc.

Provide P/FCFE
for Kymera Therapeutics Inc.

Provide P/B
for Kymera Therapeutics Inc.

Provide EV/S
for Kymera Therapeutics Inc.

Provide EV/GP
for Kymera Therapeutics Inc.

Provide EV/EBITDA
for Kymera Therapeutics Inc.

Provide EV/EBIT
for Kymera Therapeutics Inc.

Provide EV/OCF
for Kymera Therapeutics Inc.

Provide EV/FCFF
for Kymera Therapeutics Inc.

Provide EV/IC
for Kymera Therapeutics Inc.

Show me price targets
for Kymera Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Kymera Therapeutics Inc?

How accurate were the past Revenue estimates
for Kymera Therapeutics Inc?

What are the Net Income projections
for Kymera Therapeutics Inc?

How accurate were the past Net Income estimates
for Kymera Therapeutics Inc?

What are the EPS projections
for Kymera Therapeutics Inc?

How accurate were the past EPS estimates
for Kymera Therapeutics Inc?

What are the EBIT projections
for Kymera Therapeutics Inc?

How accurate were the past EBIT estimates
for Kymera Therapeutics Inc?

Compare the revenue forecasts
for Kymera Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kymera Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kymera Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kymera Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Kymera Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kymera Therapeutics Inc with its peers.

Analyze the financial leverage
of Kymera Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Kymera Therapeutics Inc.

Provide ROE
for Kymera Therapeutics Inc.

Provide ROA
for Kymera Therapeutics Inc.

Provide ROIC
for Kymera Therapeutics Inc.

Provide ROCE
for Kymera Therapeutics Inc.

Provide Gross Margin
for Kymera Therapeutics Inc.

Provide Operating Margin
for Kymera Therapeutics Inc.

Provide Net Margin
for Kymera Therapeutics Inc.

Provide FCF Margin
for Kymera Therapeutics Inc.

Show all solvency ratios
for Kymera Therapeutics Inc.

Provide D/E Ratio
for Kymera Therapeutics Inc.

Provide D/A Ratio
for Kymera Therapeutics Inc.

Provide Interest Coverage Ratio
for Kymera Therapeutics Inc.

Provide Altman Z-Score Ratio
for Kymera Therapeutics Inc.

Provide Quick Ratio
for Kymera Therapeutics Inc.

Provide Current Ratio
for Kymera Therapeutics Inc.

Provide Cash Ratio
for Kymera Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Kymera Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Kymera Therapeutics Inc?

What is the current Free Cash Flow
of Kymera Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kymera Therapeutics Inc.

Financials

Balance Sheet Decomposition
Kymera Therapeutics Inc

Current Assets 405.3m
Cash & Short-Term Investments 374.9m
Receivables 18.8m
Other Current Assets 11.7m
Non-Current Assets 170.4m
Long-Term Investments 61.4m
PP&E 101.1m
Other Non-Current Assets 7.9m
Current Liabilities 85.7m
Accounts Payable 7.1m
Accrued Liabilities 35.2m
Other Current Liabilities 43.4m
Non-Current Liabilities 95.1m
Long-Term Debt 1.3m
Other Non-Current Liabilities 93.8m
Efficiency

Earnings Waterfall
Kymera Therapeutics Inc

Revenue
78.6m USD
Operating Expenses
-244.1m USD
Operating Income
-165.5m USD
Other Expenses
18.6m USD
Net Income
-147m USD

Free Cash Flow Analysis
Kymera Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

KYMR Profitability Score
Profitability Due Diligence

Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
20/100
Profitability
Score

Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

KYMR Solvency Score
Solvency Due Diligence

Kymera Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
63/100
Solvency
Score

Kymera Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KYMR Price Targets Summary
Kymera Therapeutics Inc

Wall Street analysts forecast KYMR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KYMR is 52.255 USD with a low forecast of 30.3 USD and a high forecast of 117.6 USD.

Lowest
Price Target
30.3 USD
8% Downside
Average
Price Target
52.255 USD
59% Upside
Highest
Price Target
117.6 USD
258% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KYMR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KYMR Price
Kymera Therapeutics Inc

1M 1M
-17%
6M 6M
+190%
1Y 1Y
0%
3Y 3Y
-21%
5Y 5Y
-1%
10Y 10Y
-1%
Annual Price Range
32.845
52w Low
10.97
52w High
43.57
Price Metrics
Average Annual Return 9.55%
Standard Deviation of Annual Returns 73.56%
Max Drawdown -88%
Shares Statistics
Market Capitalization 1.8B USD
Shares Outstanding 58 521 837
Percentage of Shares Shorted 16.62%

KYMR Return Decomposition
Main factors of price return

What is price return decomposition?

KYMR News

Other Videos

Company Profile

Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.8B USD

Dividend Yield

0%

Description

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Chemistry. Its clinical stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). Its programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Contact

MASSACHUSETTS
Watertown
200 Arsenal Yards Blvd., Suite 230, 2Nd Floor
+18572855314.0
https://www.kymeratx.com/

IPO

2020-08-21

Employees

136

Officers

Co-Founder & Chairman
Dr. Bruce L. Booth DPHIL, Ph.D.
Co-Founder, President, CEO & Director
Dr. Nello Mainolfi M.D., Ph.D.
Chief Financial Officer
Mr. Bruce N. Jacobs CFA
Chief Medical Officer
Dr. Jared A. Gollob M.D.
Chief Operating Officer
Dr. Jeremy G. Chadwick Ph.D.
Chief Legal Officer & Corporate Secretary
Ms. Ellen V. Chiniara Esq., J.D.
Show More
Head of People & Culture
Ms. Karen Weisbach
Head of Research
Dr. Juliet Williams B.A Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one KYMR stock?

The intrinsic value of one KYMR stock under the Base Case scenario is 15.674 USD.

Is KYMR stock undervalued or overvalued?

Compared to the current market price of 32.845 USD, Kymera Therapeutics Inc is Overvalued by 52%.